Antiphospholipid syndrome, “the best prophet of the future”
Authors:
- 21 February 2018
- journal article
- review article
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 28 (3) , 409-416
Abstract
The antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the occurrence of venous and arterial thromboses, often multiple, and obstetric-related adverse events in the presence of antiphospholipid antibodies (aPL). APS, first described in 1983, as thrombosis, abortion and cerebral disease, is nowadays recognised as a systemic disease with a wide constellation of clinical manifestations related to acute and chronic vascular lesions. The presence of aPL is the serological hallmark of APS representing a heterogeneous population of autoantibodies with many antigenic specificities directed to phospholipid-binding proteins, either alone or in combination with phospholipids. Many assays have been developed for aPL detection. Particularly, anticardiolipin antibodies, anti-β2-glycoprotein I antibodies and lupus anticoagulant are essential tools for APS diagnosis. The cumulative evidence indicates that aPL are pathogenic autoantibodies binding to target cells and promoting thrombosis and pregnancy complications through a wide range of pathological mechanisms not yet fully understood. Finally, the recognition of the important role of aPL to assess the individual risk of thrombosis or pregnancy complications has expanded the concept of aPL, and currently aPL profile is regarded as a major risk factor for clinical thrombotic events.Keywords
This publication has 77 references indexed in Scilit:
- Risk Scale for the diagnosis of antiphospholipid syndromeAnnals of the Rheumatic Diseases, 2011
- Autoantibodies Directed Against Domain I of Beta2-Glycoprotein ICurrent Rheumatology Reports, 2010
- ORIGINAL ARTICLE: Antiphospholipid Antibodies Induce a Pro‐Inflammatory Response in First Trimester Trophoblast Via the TLR4/MyD88 PathwayAmerican Journal of Reproductive Immunology, 2009
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006
- Antibody profiles for the diagnosis of antiphospholipid syndromeThrombosis and Haemostasis, 2005
- The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti- 2Glycoprotein I antibodiesInternational Immunology, 2004
- International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshopArthritis & Rheumatism, 1999
- Specificity of ELISA for antibody to beta 2-glycoprotein I in patients with antiphospholipid syndromeRheumatology, 1996
- Induction of antiphospholipid autoantibodies by immunization with beta 2 glycoprotein I (apolipoprotein H).Journal of Clinical Investigation, 1992
- The “Primary” Antiphospholipid SyndromeMedicine, 1989